Targeting cancer cells with vitamin B12 (cobalamin) is hampered by unwanted physiologic tissue uptake mediated by transcobalamin. Adhering to good manufacturing practice, we have developed a new 99m Tc-cobalamin derivative ( 99m Tc(CO) 3 -[(4-amido-butyl)-pyridin-2-yl-methyl-amino-acetato] cobalamin, 99m Tc-PAMAcobalamin). The derivative shows no binding to transcobalamin but is recognized by haptocorrin, a protein present in the circulation and notably expressed in many tumor cells. In this prospective study, we investigated cancer-specific uptake of 99m Tc-PAMAcobalamin in 10 patients with various metastatic tumors. Methods: Ten patients with biopsy-proven metastatic cancer were included. Dynamic imaging was started immediately after injection of 300-500 MBq of 99m Tc-PAMA-cobalamin, and whole-body scintigrams were obtained at 10, 30, 60, 120, and 240 min and after 24 h. The relative tumor activity using SPECT/CT over the tumor region after 4 h was measured in comparison to disease-free lung parenchyma. Patients 3-10 received between 20 and 1,000 mg of cobalamin intravenously before injection of 99m Tc-PAMA-cobalamin. The study population comprised 4 patients with adenocarcinomas of the lung, 3 with squamous cell carcinomas of the hypopharyngeal region, 1 with prostate adenocarcinoma, 1 with breast, and 1 with colon adenocarcinoma. Results: The median age of the study group was 61 6 11 y. Six of 10 patients showed positive tumor uptake on 99m Tc-PAMA-cobalamin whole-body scintigraphy. The scan was positive in 1 patient with colon adenocarcinoma, in 3 of 4 lung adenocarcinomas, in 1 of 3 hypopharyngeal squamous cell carcinomas, and in 1 breast adenocarcinoma. Renal uptake was between 1% and 3% for the left kidney. Predosing with cobalamin increased the tumor uptake and improved blood-pool clearance. The best image quality was achieved with a predose of 20-100 ug of cold cobalamin. The mean patient dose was 2.7 6 0.9 mSv/patient. Conclusion: To our knowledge, we report for the first time on 99m Tc-PAMA-cobalamin imaging in patients with metastatic cancer disease and show that tumor targeting is feasible.
Targeting cancer cells with vitamin B12 (cobalamin) is hampered by unwanted physiologic tissue uptake mediated by transcobalamin. Adhering to good manufacturing practice, we have developed a new 99m Tc-cobalamin derivative ( 99m Tc(CO) 3 -[(4-amido-butyl)-pyridin-2-yl-methyl-amino-acetato] cobalamin, 99m Tc-PAMAcobalamin). The derivative shows no binding to transcobalamin but is recognized by haptocorrin, a protein present in the circulation and notably expressed in many tumor cells. In this prospective study, we investigated cancer-specific uptake of 99m Tc-PAMAcobalamin in 10 patients with various metastatic tumors. Methods: Ten patients with biopsy-proven metastatic cancer were included. Dynamic imaging was started immediately after injection of 300-500 MBq of 99m Tc-PAMA-cobalamin, and whole-body scintigrams were obtained at 10, 30, 60, 120, and 240 min and after 24 h. The relative tumor activity using SPECT/CT over the tumor region after 4 h was measured in comparison to disease-free lung parenchyma. Patients 3-10 received between 20 and 1,000 mg of cobalamin intravenously before injection of 99m Tc-PAMA-cobalamin. The study population comprised 4 patients with adenocarcinomas of the lung, 3 with squamous cell carcinomas of the hypopharyngeal region, 1 with prostate adenocarcinoma, 1 with breast, and 1 with colon adenocarcinoma. Results: The median age of the study group was 61 6 11 y. Six of 10 patients showed positive tumor uptake on 99m Tc-PAMA-cobalamin whole-body scintigraphy. The scan was positive in 1 patient with colon adenocarcinoma, in 3 of 4 lung adenocarcinomas, in 1 of 3 hypopharyngeal squamous cell carcinomas, and in 1 breast adenocarcinoma. Renal uptake was between 1% and 3% for the left kidney. Predosing with cobalamin increased the tumor uptake and improved blood-pool clearance. The best image quality was achieved with a predose of 20-100 ug of cold cobalamin. The mean patient dose was 2.7 6 0.9 mSv/patient. Conclusion: To our knowledge, we report for the first time on 99m Tc-PAMA-cobalamin imaging in patients with metastatic cancer disease and show that tumor targeting is feasible. Sel ective targeting of cancer cells for imaging procedures or delivery of drugs or toxins is in focus for cancer therapy. The aim is to have a substance homing for cancer cells but nontoxic for other cells of the body. For this purpose, the use of vitamin B12 (cobalamin) delivered in a manner that favors uptake in cancer cells is advantageous. All living cells, including tumor cells, depend on cobalamin, a coenzyme for methionine synthase and methyl-malonylCoA mutase (1); furthermore, cobalamin has no known toxicity.
A complex transport process involving several soluble binding proteins and corresponding receptors ensure the transport of the vitamin from the intestine through the bloodstream to the target cell (2, 3) . Intrinsic factor, present only in the gastrointestinal tract, mediates the intestinal absorption of cobalamin. In the circulation, transcobalamin mediates the transport to the cells of the body. Two cellular receptors recognizing transcobalamin-cobalamin (holoTC) have been described. Megalin is a multifunctional receptor ensuring the uptake of holoTC filtered in the kidney, whereas the newly identified transcobalamin receptor CD320 is believed to promote the uptake of holoTC into all cells of the body, including cancer cells (4) .
For many decades it has been recognized that certain cancer cells show an increased extracellular density of receptors able to promote the uptake of holoTC (5-7), and several studies have explored the use of cobalamin labeled with radioactive cobalt isotopes ( 57 Co, 58 Co, 60 Co) for cancer imaging (8, 9) . However, all studies showed a high uptake also in the liver, kidney, spleen, nasal cavity, salivary, and lachrymal glands. The same pattern was obtained when using cobalamin labeled with 111 In, 131 I, and 99m Tc (10) (11) (12) . Especially the problem of a high kidney uptake has to be solved to use a cobalamin uptake system for cancer imaging with the potential for radionuclide therapy.
In addition to transcobalamin and intrinsic factor, a third soluble cobalamin-binding protein, haptocorrin, participates in the transport of cobalamin. Haptocorrin carries the major part of circulating cobalamin, but interestingly haptocorrin is not filtered in the kidney and no receptor recognizing haptocorrin has been identified in the kidney. The function of haptocorrin in the transport and use of cobalamin is unsettled (2, 13) . However, 2 unique features of haptocorrin are important for the concept of the present paper. Haptocorrin recognizes a broader spectrum of cobalamin derivatives than does intrinsic factor and transcobalamin, and haptocorrin may occur in an increased amount in patients with cancer (14) . Using immunohistochemistry, we have shown an increased expression of haptocorrin in samples from patients with carcinomas of the lung, prostate, uterus, and ovary as well as squamous cell carcinomas of the skin, B-cell lymphomas, seminomas, anaplastic thyroid cancer, and bladder urothelial cancer (15) . The results support and expand earlier studies on plasma levels of haptocorrin, where high levels have been encountered in patients with liver cancer and with chronic myeloid leukemia and also in patients displaying normal levels of transcobalamin (16, 17) .
We recently described a tailored vitamin B12 derivative, 99m Tc-PAMA-cobalamin ( 99m Tc(CO) 3 -[(4-amido-butyl)-pyridin-2-yl-methylamino-acetato] cobalamin) able to bind to human haptocorrin but not to human transcobalamin (15) , and using a mouse model we showed 99m Tc-PAMA-cobalamin accumulation in haptocorrinexpressing tumors with limited uptake in liver and kidney (14) . In the present study, we report the results of a pilot trial in patients with advanced cancer, exploring the role of 99m Tc-PAMA-cobalamin in a clinical setting.
MATERIALS AND METHODS

Patients
Ten patients with biopsy-proven active malignant disease were prospectively selected in this study, approved by the local ethics committee and the institutional review board. All patients gave informed consent according to our local ethics committee. Each patient had an 18 F-FDG-positive PET/CT (n 5 9) examination for visceral metastases or a positive skeletal scintigraphy (n 5 1) result confirming osseous metastases within 7 d before 99m Tc-PAMA-cobalamin scintigraphy. The patients were consecutively assigned to different presaturation protocols with cold cobalamin. No change in any medication between both examinations was allowed in the study protocol.
Preparation of 99m Tc-PAMA-Cobalamin 99m Tc-PAMA-cobalamin was prepared under the good manufacturing practice guidelines in compliance with the Swiss agency of therapeutic products (Swissmedic). Precursor [ 99m Tc(CO) 3 TcO 4 ] (1.0-1.4 mL; 6-7 GBq) was added to an Isolink kit. The kit was heated for 20 min at 95°C. After that, it was cooled to room temperature and kept for 5 min before the 350 mL of neutralization solution (1 M HCl and 0.6 M phosphate buffer: 3:2) was added. 2-(N-morpholino) ethanesulfonic acid buffer (MES buffer; 100 mL; 1 M, pH 6.2) was added. The entire [ 99m Tc(CO) 3 (OH 2 ) 3 ] 1 solution was added to a lyophilized vial containing 35 6 2 mg of EtO-PAMA-cobalamin (;20 nmol). The reaction was heated for 75 min at 70°C. The crude product was purified on a semipreparative highperformance liquid chromatography system (System Gold 126 Solvent Module, System Gold 168 UV/vis Detector, or a Spectra NaI Scintillation Detector 8ISW8/2 [Beckman Coulter]) using an XTerra RP8 column (5 mm, 3.0 · 150 mm; Waters) with a linear gradient of 14% solvent B to 70% (solvent A: 1 M acetate buffer/EtOH 10%; solvent B: ethanol 70%) in 0-20 min. From 20 to 30 min, the gradient remained constant before ramping back (from 30 to 35 min) to the initial ratio. The flow rate was 1 mL/min and ultraviolet detection at 240 nm. The product peak (maximum, 2 mL) was collected into a 25-mL vial containing 14 mL of phosphate-buffered saline (pH 7.4). After synthesis and purification, the solution was sterile-filtered.
Blood Sampling and Presaturation with Vitamin B12
Blood samples for routine measurement of cobalamin were collected before injection of 99m Tc-PAMA-cobalamin. Blood samples for clearance determination were removed 30 min, 60 min, 90 min, and 4 h after injection of 99m Tc-PAMA-cobalamin.
For the predosing of patients with cobalamin, Vitarubin Superconc (Streuli Pharma AG) was used. Patients receiving cobalamin had a single intravenous injection 1 h before the 99m Tc-PAMA-cobalamin injection. Patients 1 and 2 received no cobalamin, patients 3-6 received 20 mg, patients 7 and 8 received 100 mg intravenously, and patients 9 and 10 received 1,000 mg intravenous cobalamin.
Data Acquisition
All imaging was performed at our institution on a dedicated SPECT/ CT scanner (Infinia Hawkeye; GE Healthcare). Dynamic imaging was started immediately after injection of 300-500 MBq of 99m Tc-PAMAcobalamin with 5 s per frame and 120 frames (10 min). Thereafter, the first whole-body scintigram was started with a table speed of 30 s/cm. After 30 min, a second whole-body scintigram was obtained (table speed, 30 cm/s). This procedure was repeated after 60, 120, and 240 min (each with a table speed of 15 cm/s) and after 24 h (with a table speed of 10 cm/s). In addition, SPECT/CT was performed over the tumor region after 4 h, imaging with a step-and-shoot protocol of 30 s and a rotation angle of 3°for a total of 60 views per camera head. Images were reconstructed with iterative attenuation reconstruction on a 128 · 128 matrix. The CT (x-ray, 2.5 mA; 140 kV) had a slice thickness of 10 mm, with a scan time of approximately 10 min for a 40-cm field of view.
Data Analysis
Image analysis was performed by 2 nuclear medicine physicians in consensus. All imaging results using 99m Tc-PAMA-cobalamin were compared with either 18 F-FDG PET/CT (n 5 9) or bone scintigraphy (n 5 1). Whole-body scintigrams at 10, 30, 60, 120, and 240 min and 24 h after administration were analyzed for relative tumor uptake. A region of interest over the whole liver, bladder (urinary), left kidney, lung, mediastinum, salivary glands, soft tissue, and tumor tissue was placed. The data were normalized using a whole-body region of interest at the given time point. Data were analyzed in the anterior and posterior views using the COMPARE ROI ANALYSIS algorithm in the Xeleris Workstation (GE Healthcare Biosciences).
The normalized activities were taken as relative activity after injection of 1 MBq of 99m Tc. From these activities, the effective remaining activities were calculated with the half-life for 99m Tc of 6 h. Between each time point, the effectively remaining activity (i.e., area under the curve) was estimated with the calculation over trapezoids (time difference multiplied by the height). Afterward, the area of the trapezoids for the different time points was summed. The results presented the input data of the software OLINDA, which calculates the specified organ doses in mSv/MBq. Finally, the doses were multiplied by the injected dose in megabecquerel per patient to get the effective dose per patient (mSv/patient).
99m Tc-PAMA-cobalamin scintigrams were compared with recent 18 F-FDG PET/CT data (n 5 9) or 99m Tc-methylene diphosphonate bone scintigraphy (n 5 1). The primary tumor was imaged with SPECT/CT after 4 h. Tumor-to-background activity ratios were estimated using normal lung tissue as background reference (kBq/cm 3 ) using dedicated software for SPECT image analysis (PMOD 3.3; PMOD Technologies). Tc-PAMA-cobalamin in blood samples was analyzed using a standard g ray detector. Blood clearance (t 1/2 ) was calculated using injected dose per blood volume as injected reference concentration and decay-corrected blood-pool activities at 30, 60, 90, and 240 min. Exponential blood-pool elimination with 0 noise and no constraints was assumed, and blood-pool half-life was calculated with the leastsquare fitting method (MATLAB 7.9.0; The MathWorks).
RESULTS
Patient Demographics
Ten patients with various metastasized tumors were prospectively selected. The median age of the study group was 61 (range, 47-84 y) years. Four patients presented with adenocarcinomas of the lung, 3 with squamous cell carcinomas of the hypopharyngeal region, 1 with prostate adenocarcinoma, 1 with adenocarcinoma of the breast, and 1 with colon adenocarcinoma. Patient demographics are summarized in Table 1 .
Qualitative Imaging Results of 99m Tc-PAMA-Cobalamin Scintigraphy
Six of 10 patients with metastatic cancer had positive tumor delineation in 99m Tc-PAMA-cobalamin scintigraphy. The 99m Tc-PAMA-cobalamin scintigraphy result was positive in 1 patient with metastatic colon adenocarcinoma (patient 3), in 3 of 4 lung adenocarcinomas (patients 4, 7, and 8), in 1 of 3 hypopharyngeal squamous cell carcinomas (patient 5), and in 1 breast adenocarcinoma (patient 9). The 99m Tc-PAMA-cobalamin scintigraphy result remained negative in 1 patient with prostate cancer with bone metastases (patient 6), 2 of the hypopharyngeal carcinomas (patients 1 and 2), and 1 lung cancer (patient 10). Lesion characteristics are summarized in Table 1 .
Patients 1 and 2 suffered from hypopharyngeal squamous cell cancer. 99m Tc-PAMA-cobalamin scintigraphy showed no focal uptake in the biopsy-proven and 18 F-FDG-active tumor tissue.
Patient 3 had a colon adenocarcinoma of the left colic flexure. At the time of the study scans, the primary tumor was resected. 18 F-FDG PET/CT showed metastases in the liver, in the left psoas muscle and between the 10th and 11th left rib. 99m Tc-PAMA-cobalamin scintigraphy showed focal uptake in the liver metastases.
Patient 4 suffered from bronchial adenocarcinoma. 99m Tc-PAMA-cobalamin scintigraphy showed high relative uptake of a factor of 45.0, compared with normal lung tissue in the primary tumor, and some focal uptake in mediastinal lymph nodes. 18 F-FDG PET/CT further delineated 2 local bone metastases not avid on 99m Tc-PAMA-cobalamin scintigraphy (Fig. 1) .
Patient 5 suffered from hypopharyngeal squamous cell cancer. 99m Tc-PAMA-cobalamin scintigraphy showed intense uptake (tumor-to-background ratio, 55.6) in the right cervical lymph node and some lower focal uptake in the primary tumor in the central neck. 18 F-FDG PET/CT in this patient showed intense uptake in the primary tumor and in local cervical lymph node metastases bilaterally on level II/III and V (Fig. 2) .
Patient 6 had a radical prostatectomy 2 y prior because of prostate adenocarcinoma. At the time of study, bone scintigraphy showed metastases in the left and right os ilium, whereas 99m Tc-PAMA-cobalamin scintigraphy showed no relevant radiotracer uptake.
Patients 7 and 8 had bronchial adenocarcinomas. Both primary tumors were positive on 99m Tc-PAMA-cobalamin scintigraphy, with a tumor-to-background ratio of 14.7 and 5.6, respectively. 18 F-FDG PET/CT showed additional metastases in both patients. An overview of injected 99m Tc-PAMA-cobalamin doses and presaturation with cobalamin and the calculated tumor-to-background ratios and overall dose per patient are given in Table 2 . The mean patient dose was 2.7 6 0.9 mSv/patient (range, 1.8-4.8 mSv/patient).
In patients without cobalamin predose (patients 1 and 2), tumor tissue was not detectable on whole-body scintigrams (Fig. 3) . The high values for lung (mean, 11.2%) and mediastinum (mean, 7.8%) reflect the high blood-pool activity over 24 h in both patients. The mean relative organ uptake for liver, salivary glands, and kidney was 14.6%, 3.3%, and 2.3%, respectively.
In patients who received cobalamin 60 min before injection of 99m Tc-PAMA-cobalamin, the biodistribution pattern was significantly different. Tumor lesions were identified in 6 of 8 patients, with an average uptake of 4.6% of the injected dose to the tumors. The percentage activity in the tumors remained stable over 24 h, without significant washout (Fig. 3) . The mean relative organ uptake after 20-100 mg of cobalamin for liver, salivary glands, and kidney was 20.9%, 3.6%, and 2.0%, respectively. Compared with the group without cobalamin, liver uptake in patients with cobalamin predose was considerably higher (Fig. 4) . However, after predosing with 1,000 mg of cobalamin the mean organ activity for tumor tissue, liver, and salivary glands decreased to 0.5%, 4.3%, and 1.2%, respectively, whereas the renal activity remained around 2.0%. Relative tumor and organ uptake values 2 h after injection of 99m Tc-PAMA-cobalamin are presented Table 3 .
Blood Clearance of 99m Tc-PAMA-Cobalamin
For patients without cobalamin predosing, radioactivity in the blood pool cleared with a half-life of about 10 h. In patients receiving cobalamin before 99m Tc-PAMAcobalamin, the half-life of the tracer in the blood was on average t 1/2 5 18 min (19 min for patients receiving 20-100 mg of cobalamin and 15.7 min for patients receiving 1,000 mg of cobalamin; Fig. 5 ).
DISCUSSION
This is the first, to our knowledge, clinical study confirming that a tailored cobalamin derivative with abolished interaction to the transport protein transcobalamin but preserved affinity to haptocorrin can be used to visualize tumors in humans. It confirms results from an earlier preclinical study using a mouse model (14) . Several publications investigated cobalamin as a potential tumor tracer (8) (9) (10) (11) (12) . First, the simple use of 57 Co-cyano-cobalamin confirmed an increased uptake in malignant cells (8) , but the long half-life of 57 Co (272 d) restricted its use for clinical imaging. An 111 In-labeled diethylenetriaminepentaacetic acid (DTPA) adenosylcobalamin ( 111 In-DAC) with favorable dosimetry confirmed an increased tumor activity, however, with remaining high activities in the liver, spleen, kidney, and salivary glands. This has generally been attributed to the fact that the radiotracers bind to transcobalamin and hence are distributed to all cells carrying receptors for transcobalamin (10) .
Similar to the results with 111 In-DAC, the new vitamin B12 derivative 99m Tc-PAMA-cobalamin showed increased uptake in the salivary glands and liver. However, the abolished interaction to transcobalamin led to a reduction of renal organ dose, with an average uptake of 3.2% of the whole-body uptake in the left kidney after 10 min and a further decrease to 2% after 60 min and 1.7% after 24 h (Fig. 3) . Collins et al. described an increased tumor uptake with optimized visualization for patients with high blood-pool levels of cobalamin before injection of 111 In-DAC and suggested that the saturation of blood-pool transport protein could increase the tumor uptake (20) . Our first 2 patients investigated without cobalamin predose confirmed a high blood-pool activity over 24 h, most likely due to tracer binding to apo-haptocorrin, which amounts to about 22 mg of blood per liter (0.3 nmol/L) in a normal healthy individual (21) . Considering the small amount of PAMA-cobalamin injected per patient (;0.1-0.2 nmol), it is not surprising that most of the radiotracer bound to circulating haptocorrin. This would also coincide with the slow blood clearance, because haptocorrin-bound cobalamin is cleared from plasma with a t 1/2 of 9-12 d (22) . The half-life of our tracer in the blood of patients without cobalamin was about 10 h, what corresponds closely to the effective half-life of a holohaptocorrin-99m Tc-PAMA-cobalamin complex. After cobalamin predosing, 99m Tc-PAMA-cobalamin was excreted faster (average t 1/2 5 18 min) and had a lower blood-pool activity, presumably because the circulating haptocorrin was presaturated, therefore, relative liver and tumor uptake increased. However, after an injection of 1,000 mg of cobalamin the relative liver and tumor activities were significantly reduced, probably due to an oversaturation of haptocorrin in the blood and in organs and malignancies. In 5 of 6 patients receiving 20 or 100 mg of cobalamin, at least 1 lesion was visualized on the 99m Tc-PAMA-cobalamin scintigram, with the highest tumor-to-background ratios after 20 mg of cobalamin. We therefore suggest that a range of 20-100 mg of cobalamin could yield the best image quality. 18 F-FDG PET/CT had the higher maximum standardized uptake value in the primary tumor, compared with the cervical lymph node (Fig. 2) . Interestingly, 99m Tc-PAMA-cobalamin scintigraphy showed the opposite: higher tracer uptake in the cervical lymph node metastasis than in the primary tumor. Histology work-up of this case showed a vital lymph node metastasis and large necrotic areas with inflammatory components within the primary tumor. However, 18 F-FDG PET/CT correctly staged this patient as cT4cN2cM0, because of contralateral lymph nodes, and therefore showed a relevant upstaging from N1 to N2c, compared with 99m Tc-PAMA-cobalamin scintigraphy. In this proof-of-concept study, several different tumor types were analyzed. The resulting heterogeneous patient group is limiting the current study. However, previous immunohistochemistry studies for haptocorrin distribution on variable tumor cell lines revealed an overexpression in a large variety of different carcinomas (15) . Our study confirmed an increased uptake of 99m Tc-PAMA-cobalamin in bronchial adenocarcinoma, squamous cell cancer of the head and neck, breast cancer, and colon cancer.
Because of the small numbers and the heterogeneity of our study, we could not determine any disease-specific sensitivities or specificities for 99m Tc-PAMA-cobalamin. Nevertheless, it is the first study in humans confirming that selective tumor imaging with 99m Tc-PAMA-cobalamin is feasible in a large variety of different tumor histologies and shows a low renal uptake. Further studies with larger samples of patients with optimal predosing are needed.
CONCLUSION
In vivo tumor visualization is possible with the cobalamin derivative 99m Tc-PAMA-cobalamin. After pretreatment with cobalamin to saturate circulating haptocorrin, the tracer accumulates in tumor tissue, liver, and salivary glands but not in the radiosensitive kidneys. Although the overall sensitivity was low, compared with 18 F-FDG PET/CT, the present results may pave the road for further development of radiotherapeutic drugs.
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